Cited by 91Radiomics and Machine Learning in Medical ImagingAI in cancer detectionLung Cancer Diagnosis and Treatment

Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study

Open access
She, Yunlang, He, Bingxi, Wang, Fang, Zhong, Yifan, Wang, Tingting, Liu, Zhenchuan, Yang, Minglei, Yu, Bentong +10 more·2022·eBioMedicine

Abstract

BACKGROUND: This study, based on multicentre cohorts, aims to utilize computed tomography (CT) images to construct a deep learning model for predicting major pathological response (MPR) to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC) and further explore the biological basis under its prediction. METHODS: 274 patients undergoing curative surgery after neoadjuvant chemoimmunotherapy for NSCLC at 4 centres from January 2019 to December 2021 were included and divided into a training cohort, an internal validation cohort, and an external validation cohort. ShuffleNetV2x05-based features of the primary tumour on the CT scans within the 2 weeks preceding neoadjuvant administration were employed to develop a deep learning score for distinguishing MPR and non-MPR. To reveal the underlying biological basis of the deep learning score, a genetic analysis was conducted based on 25 patients with RNA-sequencing data. FINDINGS: MPR was achieved in 54.0% (n = 148) patients. The area under the curve (AUC) of the deep learning score to predict MPR was 0.73 (95% confidence interval [CI]: 0.58-0.86) and 0.72 (95% CI: 0.58-0.85) in the internal validation and external validation cohorts, respectively. After integrating the clinical characteristic into the deep learning score, the combined model achieved satisfactory performance in the internal validation (AUC: 0.77, 95% CI: 0.64-0.89) and external validation cohorts (AUC: 0.75, 95% CI: 0.62-0.87). In the biological basis exploration for the deep learning score, a high deep learning score was associated with the downregulation of pathways mediating tumour proliferation and the promotion of antitumour immune cell infiltration in the microenvironment. INTERPRETATION: The proposed deep learning model could effectively predict MPR in NSCLC patients treated with neoadjuvant chemoimmunotherapy. FUNDING: This study was supported by National Key Research and Development Program of China, China (2017YFA0205200); National Natural Science Foundation of China, China (91959126, 82022036, 91959130, 81971776, 81771924, 6202790004, 81930053, 9195910169, 62176013, 8210071009); Beijing Natural Science Foundation, China (L182061); Strategic Priority Research Program of Chinese Academy of Sciences, China (XDB38040200); Chinese Academy of Sciences, China (GJJSTD20170004, QYZDJ-SSW-JSC005); Shanghai Hospital Development Center, China (SHDC2020CR3047B); and Science and Technology Commission of Shanghai Municipality, China (21YF1438200).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2022.104364

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 26 references couldn’t be matched to a known paper.

Research works printed but not linked: 5

  1. [1]National Comprehensive Cancer Network. (NCCN) Clinical practice guidelines in oncology. Non-small cell lung cancer, version 1. 2022 [Internet] https://www.nccn.org/professionals/physician_gls/default.aspx 35545176
  2. [18]Ma N. Zhang X. Zheng H.-T. Sun J. Shufflenet v2: practical guidelines for efficient cnn architecture design. Proceedings of the European conference on computer vision (ECCV) 2018
  3. [19]He K. Zhang X. Ren S. Sun J. Deep residual learning for image recognition. Proceedings of the IEEE conference on computer vision and pattern recognition 2016
  4. [20]Huang G. Liu Z. Van Der Maaten L. Weinberger K.Q. Densely connected convolutional networks. Proceedings of the IEEE conference on computer vision and pattern recognition 2017
  5. [21]Howard A. Sandler M. Chu G. Searching for mobilenetv3. Proceedings of the IEEE/CVF international conference on computer vision 2019

Cited by

Sorted by citations

Authors
She, Y., He, B., Wang, F., Zhong, Y., Wang, T., Liu, Z., Yang, M., Yu, B., Deng, J., Sun, X., Wu, C., Hou, L., Zhu, Y., Yang, Y., Hu, H., Dong, D., Chen, C., & Tian, J.
Affiliations
  • Tongji University (CN)
  • Chinese Academy of Sciences (CN)
  • Sir Run Run Shaw Hospital (CN)
  • First Affiliated Hospital of Nanchang University (CN)
  • Xidian University (CN)
Corresponding author
  • Hu, Hongjie
  • Dong, Di
  • Chen, Chang
  • Tian, Jie
Venue
eBioMedicine
Publisher
Elsevier BV
Published
2022-12
Volume
86
Pages
104364
ISSN
2352-3964 (ISSN-L)
OpenAlex
W4308946414
Cited by
91
References
26
Citations by year
2026: 15 · 2025: 37 · 2024: 26 · 2023: 13
FWCI
10.80
Type
journal article
Language
en
Open access
Locations
  • EBioMedicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Key Research and Development Program of China (2017YFA0205200)
  • National Natural Science Foundation of China (6202790004, 62176013, 81771924, 81930053, 81971776, 82022036, 8210071009, 9195910169, 91959126, 91959130)
  • Chinese Academy of Sciences (GJJSTD20170004, QYZDJ-SSW-JSC005, XDB38040200)
  • Science and Technology Commission of Shanghai Municipality (21YF1438200)
  • Natural Science Foundation of Beijing Municipality (L182061)
  • Shanghai Hospital Development Center (SHDC2020CR3047B)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
  • Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
non-small cell lung cancer, neoadjuvant chemoimmunotherapy, major pathological response, deep learning prediction, computed tomography, ShuffleNetV2, tumor immune microenvironment, RNA sequencing, tumor suppressor, prognostic factors, treatment response prediction
MeSH terms
Deep Learning, Carcinoma, Non-Small-Cell Lung, China, Humans, Lung Neoplasms, Retrospective Studies, Neoadjuvant Therapy, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review